VBCG
BIO icon

Valley Brook Capital Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Valley Brook Capital Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-115
Closed -$65K – 143
2021
Q1 		$65K Buy
115
+55
+92% +$32.6K 0.06% 195
2020
Q4 		$34K Buy
+60
New +$34.2K 0.03% 231

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Valley Brook Capital Group's BIO Position: Q2 2021 in Review

Valley Brook Capital Group sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2021, closing a stake of 115 shares — an estimated $65K sold.

Valley Brook Capital Group first reported a position in BIO in Q4 2020 and held it in 2 quarters. The position peaked at $65K in Q1 2021. 509 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

  • Valley Brook Capital Group reported no remaining Bio-Rad Laboratories Class A position as of Q2 2021 after selling out during the quarter.
  • Valley Brook Capital Group sold 115 Bio-Rad Laboratories Class A shares in Q2 2021, an estimated $65K.
  • Valley Brook Capital Group first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 2 quarters.
  • Valley Brook Capital Group's Bio-Rad Laboratories Class A position peaked at $65K in Q1 2021.
  • 509 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on Valley Brook Capital Group's 13F filing for Q2 2021, filed 22 Jul 2021.